|
|
Post by trenddiver on Jan 15, 2015 1:42:02 GMT -5
Can't wait for next month for next month could be one of the most exciting months in the history of the Company.
First, the launch of Afrezza which is what we have all been waiting for. For many of us investors, especially those who stayed in or invested during the bleak times, the launch will be "sweet victory".
Second, Mannkind is going to be finalizing its direction for the next generation of products utilizing the Technosphere platform. I'll be very interested to see what the experts that Mannkind hired to make these recommendations came up with. As Hakan said, Mannkind proved the viability of Technosphere with a most difficult desease. I believe that Mannkind's next series of products are going to be huge blockbusters for that's how Al Mann thinks and Hakan is an able decipel. Hakan will do an excellent job running the company and Al will be always be there for guidance and money (if necessary). I'd rather not speculate on Al not being around.
Anyhow, happy days are just a month or so way. Enjoy the ride.
Trend
|
|
|
|
Post by trenddiver on Jan 12, 2015 10:53:36 GMT -5
I'm wondering why MNKD would be fronting the partnership capital expenditures and then being reimbursed on some differed basis as product is sold as opposed to be reimbursed by the partnership on an ongoing basis as money is spent. Do we know how they are amortizing these capital expenditures and how long it will take to get reimbursed? Is Matt correct that MNKD is selling the product to Sanofi as opposed to the partnership? Will there be any manufacturing profit to MNKD built into the price or is MNKD doing this free?
Trend
|
|
|
|
Post by trenddiver on Jan 9, 2015 11:35:13 GMT -5
Battle being fought at 50 day MA currently at $5.74. Internal momentum indicators both daily and weekly are constructive for continual increase in PPS. Share price has moved to the upside out of a triangle formation. I am looking for the share price to continue to the upside and test the 200 day MA currently at $7.08 within the next month.
Trend
|
|
|
|
Post by trenddiver on Jan 9, 2015 0:56:52 GMT -5
Also known as MKC 180. Mannkind has been investigating this hormone in connection with weight loss for at least 5 years. This is a perfect application for the Technosphere technology. MKC 180 was put on the back burner so the company's resources could be directed towards the success of Afrezza. Mannkind must be moving this up to the front burners now that Afrezza is on the launch pad with Sanofi. Billions are spent annually on weight loss. This could be the "next big thing" for Mannkind.
Trend
|
|
|
|
Post by trenddiver on Jan 8, 2015 9:25:37 GMT -5
Maybe some clarity on the launch will be given at the JPM Conference Jan 12-14. Both Sanofi and Mannkind will be giving presentations.
Trend
|
|
|
|
Post by trenddiver on Jan 8, 2015 9:12:56 GMT -5
Get ready for another hit piece.
Trend
|
|
|
|
Post by trenddiver on Dec 24, 2014 11:43:25 GMT -5
Some of the important internal indicators (MACD, RSI) have turned bullish indicating higher prices to come. The 50 day moving average is at $5.78 which should offer some resistance. The next stop looks to be at $6.50-$6.60 (recent high) and then maybe a run test the 200 day moving average at $7.06.. Happy holidays and GLTA.
TREND
|
|
|
|
Post by trenddiver on Dec 4, 2014 23:14:17 GMT -5
The Afrezza boat has already sailed. There is really nothing for Mannkind to say about the Sanofy situation. What they should be talking about is the next product. We should not have to wait until after Afrezza launches for an update on the next project. Who would want to invest in a company without knowing what prospects are on the horizon. They have been silent about this since the Annual Shareholders Meeting.
Trend
|
|
|
|
Post by trenddiver on Dec 4, 2014 19:52:58 GMT -5
Hi JPG,
Yes your right. It used to be $4 bil, now $2.4 bil. Even my friends on the golf course say I'm the worst scorekeeper out there. Glad I got out of accounting. That being said, it was easy being the CFO of this $100 mil company with Big Al bankrolling it. Now, it's difficult because we need large institutions and other Wall Streeters betting with us, not against us. We need a new interface with Wall Street.
Trend
|
|
|
|
Post by trenddiver on Dec 4, 2014 19:20:56 GMT -5
Each member of management has a job to do, and the only member of management I have an issue with is Matt Pheffer. Being a former CPA myself, and having personally spoken with him I just don't believe he is the right person for managing the crucial role of communicating with Wall Street and Mannkind's own CPA's. I will present examples of what I mean:
1. His past statements about the MNKD's ability to utilize the existing insulin inventory was at best misleading.
2. His statement at the Morgan Stanley Healthcare Conference on September 10, 2014 was just plain stupid "Mannkind was starved for cash and just made it to the finish line"
3. His failure to push back to his own CPA's about the accounting treatment for the $150,0000,000 milestone and future milestone payments. Although the 3rd qtr 10-Q states that "in order for revenue to be recognized, the Sellers price to the buyer must be fixed, determinable and not subject to refund or adjustment.". Clearly the $150,000,000 meets those criteria. Yet Mannkind has chosen to go along with the most conservative accounting treatment possible, which is " the Company has determined that it does not have the ability to determine the costs that would be associated with the loss share agreement and therefore the requirement for revenue recognition has not been met." That is a ridiculous interpretation. Using that standard might mean that the company will never be able to recognize milestone payment revenue. And his explanation to the Wall Street folks was almost unintelligible leaving the open the possibility that the $150,000,000 milestone payment and other milestone payments might be refundable.
4. His statement that any announcement of future agreements regarding Technosphere will have to wait until after the launch of Afrezza. That statement is just fodder for the shorts. Surely he could have left investors with a better takeaway.
5. He has no strategy to deal the large short position, in fact almost everything he says plays right into their hands.
6. Take a look at his resume, his inexperience as a CFO is weak.
In conclusion there are great CFO's out there in the biotech world that are both respected by Wall Street and feared by short interest hedge funds. What we have is a $4 billion company whose dealings with Wall Street are being managed by a minor leaguer.
Trend
|
|
|
|
Post by trenddiver on Dec 4, 2014 16:29:38 GMT -5
Time for Matt Pheiffer to move on. Maybe Al can transfer him to his new IPO EYES. if there is any one person responsible for the poor performance of Mannkind stock, it is Matt Pheiffer. If I didn't know better, I'd say he was employed by one of the short hedge funds. He just doesn't know what to say to Wall Street investors. And most of the time he sounds like a bumbling fool. I say, bring in a new experienced CFO to manage Wall Street and come up with a strategy to deal with the huge short interest. Matt is too inexperienced to be managing the financial aspects of a 4 billion dollar entity. We deserve better.
Trend
|
|
|
|
Post by trenddiver on Dec 1, 2014 22:30:54 GMT -5
Just wondering, would the investor be able to lend out the shares
and earn the 12.5% in addition to selling the puts?
|
|
|
|
Post by trenddiver on Dec 1, 2014 22:29:41 GMT -5
Fwiw, I'm pretty sure the 970k share purchase today was used for the large call activity like someone mentioned. They bought 970k shares for 5.7mil then wrote 9700 or so $4.50 feb calls for $1.45 and collected $1,400,000. I'm struggling with the why part? In order to maximize profit they would want it under 4.50 by feb so the shares don't get called away then expect it higher than 6 after? Or is this a hedge against a huge short position? Anyone have ideas? Well, that certainly would explain why shorts are not covering. Perhaps the expectation is that this will drop heavily right before it reacts to sells and goes up. |
|
|
|
Post by trenddiver on Nov 11, 2014 13:54:46 GMT -5
The warrants MNKDW with Jan 16 exercise are selling at a discount to the MNKD share price. The all in cost by purchasing and exercising the warrant is $5.98 per share. The share price is currently at $6.08. You are able to buy at a discount and get the time value for free. This arbitrage probably won't last long.
Trend
|
|
|
|
Post by trenddiver on Nov 6, 2014 12:48:48 GMT -5
|
|
